Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

Abstract

Our data confirm that Navelbine has major single-agent antitumor activity as front-line therapy in advanced breast cancer. Given its excellent tolerance profile and low toxicity, it should be considered for inclusion in first-line combination chemotherapy regimens.